Sight Sciences Publishes 36-Month Analysis of OMNI Surgical System for Primary Open-Angle Glaucoma

Sight Sciences has announced the publication of a comprehensive 36-month analysis evaluating the long-term effectiveness of the OMNI Surgical System in managing primary open-angle glaucoma (POAG). This study, led by Nathan M. Radcliffe, MD, from the Mount Sinai School of Medicine in New York City, was published in the American Journal of Ophthalmology and utilized data from the American Academy of Ophthalmology IRIS Registry.

Insights from the Study

Dr. Radcliffe highlighted the significance of the findings in a press release, stating,

“This analysis represents one of the most comprehensive, real-world evaluations of standalone canaloplasty and trabeculotomy in these patient populations to date. Our findings underscore the ability of OMNI to achieve significant and sustained reductions in IOP and medication use over three years, reinforcing its position as a highly effective interventional treatment for patients with primary open-angle glaucoma.”

Key Study Results

The study included 230 eyes of 196 patients with POAG, tracking their progress for up to 36 months. Here are the primary findings:

       • Intraocular Pressure (IOP) Reduction:

               • Significant reductions in IOP were observed postoperatively, ranging from 5.6 to 7.1 mmHg over 36 months.

               • Patients with higher baseline IOP (≥18 mmHg) experienced reductions of up to 8.9 mmHg.

               • The mean baseline IOP was 22.1 mmHg (±6.4 mmHg). Over the follow-up period, mean IOP ranged from 15.1 to 16.7 mmHg.

       • Reduction in Medication Use:

                • A decrease in the use of glaucoma medications was observed in both high and low baseline IOP groups.

               • The mean number of medications at baseline was 2.1, decreasing to a range of 1.1 to 1.6 between 6 and 36 months postoperatively.

Implications for Glaucoma Management

The OMNI Surgical System is designed to perform canaloplasty followed by trabeculotomy, offering a dual mechanism to reduce intraocular pressure in adult patients with POAG. The study underscores its potential as a durable and effective option for reducing IOP and dependence on medications, benefiting a broad range of glaucoma patients.

This 36-month analysis reinforces OMNI’s role as a reliable, interventional treatment for primary open-angle glaucoma, addressing critical needs in long-term glaucoma management.